Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aung Naing

Showing results (121-130 of 397) with videos related to

Pageof 40
Sort By:
Hepato-Gastroenterology|March 18, 2014
Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson ExperienceApostolia M Tsimberidou, Christos Vaklavas, Siqing Fu, et al.
JCO Global Oncology|June 15, 2021
Strengthening Pathology Capacity to Deliver Quality Cancer Care in Cities in LMICsSilvina Frech, Luis Eduardo Bravo, Ingrid Rodriguez, et al.
The Oncologist|February 23, 2011
Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinicFilip Janku, Apostolia M Tsimberidou, Xuemei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2011
A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignanciesJohn W Moroney, Matthew P Schlumbrecht, Thorunn Helgason, et al.
Plos One|August 11, 2011
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancersFilip Janku, J Jack Lee, Apostolia M Tsimberidou, et al.
Investigational New Drugs|September 16, 2010
A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumorsAung Naing, Razelle Kurzrock, Laurel M Adams, et al.
European Journal of Immunology|September 19, 2019
Exposure to anti-PD-1 causes functional differences in tumor-infiltrating lymphocytes in rare solid tumorsCaitlin A Creasy, Marie-Andrée Forget, Gopal Singh, et al.
Investigational New Drugs|June 6, 2009
A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancerStacy Moulder, Navneet Dhillon, Chaan Ng, et al.
Cancer Chemotherapy and Pharmacology|May 14, 2014
Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumorsJohanna C Bendell, David S Hong, Howard A Burris, et al.
Cancer Chemotherapy and Pharmacology|March 21, 2016
Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastasesSiqing Fu, Kirk S Culotta, Gerald S Falchook, et al.
Pageof 40

Showing results (121-130 of 397) with videos related to

Sort By:
Pageof 40
Hepato-Gastroenterology|March 18, 2014
Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson ExperienceApostolia M Tsimberidou, Christos Vaklavas, Siqing Fu, et al.
JCO Global Oncology|June 15, 2021
Strengthening Pathology Capacity to Deliver Quality Cancer Care in Cities in LMICsSilvina Frech, Luis Eduardo Bravo, Ingrid Rodriguez, et al.
The Oncologist|February 23, 2011
Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinicFilip Janku, Apostolia M Tsimberidou, Xuemei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2011
A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignanciesJohn W Moroney, Matthew P Schlumbrecht, Thorunn Helgason, et al.
Plos One|August 11, 2011
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancersFilip Janku, J Jack Lee, Apostolia M Tsimberidou, et al.
Investigational New Drugs|September 16, 2010
A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumorsAung Naing, Razelle Kurzrock, Laurel M Adams, et al.
European Journal of Immunology|September 19, 2019
Exposure to anti-PD-1 causes functional differences in tumor-infiltrating lymphocytes in rare solid tumorsCaitlin A Creasy, Marie-Andrée Forget, Gopal Singh, et al.
Investigational New Drugs|June 6, 2009
A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancerStacy Moulder, Navneet Dhillon, Chaan Ng, et al.
Cancer Chemotherapy and Pharmacology|May 14, 2014
Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumorsJohanna C Bendell, David S Hong, Howard A Burris, et al.
Cancer Chemotherapy and Pharmacology|March 21, 2016
Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastasesSiqing Fu, Kirk S Culotta, Gerald S Falchook, et al.
Pageof 40